| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S13853 R54284 |
Kayser - Metoprolol/bisoprolol, 2020 | Neonatal disorders (bradycardia, hypoglycemia or respiratory disorders) | days before delivery | prospective cohort | unexposed, disease free | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 1.50 [0.70;3.00] | 29/252 38/588 | 67 | 252 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13811 R54139 |
Chan - Labetalol, 2010 | Neonatal Complications | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched | 4.25 [1.51;11.98] C | 16/32 8/42 | 24 | 32 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13392 R51825 |
Ray - Beta-blockers, 2001 | Neonatal composite disorder (disease of prematurity (i.e., necrotizing enterocolitis, periventricular hemorrhage and/or hyaline membrane disease), need for assisted ventilation and/or perinatal death) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: Yes Indications Antihypertensive: Only chronic hypertension indication | 1.40 [0.60;3.40] | 38/144 32/247 | 70 | 144 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.93 [1.02;3.62] | 161 | 428 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded